Antinuclear antibodies in dermatology

descriptionPublicationkeyboard_double_arrow_right Article 01 Mar 2001 English Publisher:Frontline Medical Communications, Inc.Journal:Seminars in Cutaneous Medicine and Surgery, volume 20, pages 2-13 (issn: 1085-5629,

Copyright policy )

Authors: M P, Heffernan; J H, Do; J, Mehta;

doi: 10.1053/sder.2001.23089

pmid: 11308133

Antinuclear antibodies in dermatology

- Summary
- Subjects
- Metrics

Abstract

Antinuclear antibodies are used in the diagnosis and evaluation of patients with connective tissue diseases. The study of antinuclear antibodies has also fundamentally expanded our understanding of nuclear anatomy and function. This article reviews the clinically relevant antinuclear antibodies and their disease associations. Developing an understanding of the utilities and limitations of antinuclear antibodies is essential to providing the expert diagnoses prognoses, and care expected of a dermatologist.

Related Organizations

University of Mary
United States
Washington University in St. Louis
United States

Keywords

Scleroderma, Systemic, Antibodies, Antinuclear, Lupus Erythematosus, Cutaneous, Fluorescent Antibody Technique, Humans, Lupus Erythematosus, Systemic, Connective Tissue Diseases, Skin Diseases, Autoantibodies

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	12
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%